GMXAY News and Press, Genmab A/S S/Adr

BioNTech ( NASDAQ: BNTX ) and Genmab ( GMAB ) are expanding their collaboration to develop and commercialize novel immunotherapies to treat patients with cancer. Under the new agreement, the companies will jointly develop and commercialize, subject to regulato...

Genmab A/S ( OTCPK:GMXAY -2.1% ) announces that licensee Johnson & Johnson ( JNJ -1.7% ) unit Janssen Biotech has launched its U.S. marketing application seeking approval to use Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone, in treatment-...

Fresenius Medical Care ( FMS +1.5% )( OTCPK:FMCQF )( OTCPK:FSMEM ) assumed with Hold rating and €82 price target at Jefferies. More news on: Fresenius Medical Care AG & Co. KGAA, Fresenius Medical Care AG & Co KGaA, Fresenius Medical Care Holdings, Healthcare stocks news, ...

As expected, the European Commission approves Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's DARZALEX (daratumumab), combined with Takeda Pharmaceutical's ( OTCPK:TKPYY ) VELCADE (bortezomib), melphalan and prednisone, for the treatment of adult patients with multiple myeloma in...

By Tajinder Dhillon 18Q2 earnings season is underway with 34 companies reporting last week ending August 10, 2018. Exhibit 1 provides a summary of reporting results. Exhibit 1: Earnings Season Results Overall Recap Of the companies that reported last week, 44% beat EPS expectatio...

The following slide deck was published by Genmab A/S in conjunction with their 2018 Q2 earnings Read more ...

Verastem ( VSTM +5.1% ) is up on average volume in apparent response to Genmab's ( OTCPK:GNMSF )( OTCPK:GMXAY ) failed late-stage study of Arzerra (ofatumumab) in indolent B-cell non-Hodgkin lymphoma. Ofatumumab, a CD-20-directed monoclonal antibody, is currently approved in the U.S. t...

Genmab A/S ( OTCPK:GNMSF )( OTCPK:GMXAY )  announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically ...

The following slide deck was published by Genmab A/S ADR in conjunction with this Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. U.S. Treasury Secretary Steven Mnuchin is scheduled to lead a delegation to China f...